As reported in ovarian cancer[30], it is possible that the higher pre-existing CD8+ TILs in the TME are activated and mediate their anti-tumour effect as a result of immunogenic cell death induced by the chemotherapy. The gene discussed is CD8A; the disease is ovarian carcinoma.